Cargando…

Debate on Treating Oligometastatic Metastatic Hormone-sensitive Prostate Cancer: The Argument for New-generation Hormone Therapy and Radiation Therapy to the Prostate

Detalles Bibliográficos
Autor principal:	Saad, Fred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Letter: Open Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789384/ https://www.ncbi.nlm.nih.gov/pubmed/36573247 http://dx.doi.org/10.1016/j.euros.2022.10.020

Ejemplares similares

Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer
por: Baron, D., et al.
Publicado: (2023)

Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer
por: Bhattasali, Onita, et al.
Publicado: (2013)

The role of hormone therapy and chemotherapy in oligometastatic prostate cancer
por: Miura, Yuji, et al.
Publicado: (2019)

Treatment Intensification for Low-risk Metastatic Hormone-sensitive Prostate Cancer: The Time Is Now
por: McKay, Rana R.
Publicado: (2022)

Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer
por: Jazayeri, Seyed Behzad, et al.
Publicado: (2022)

Radiotherapy is the Preferred Primary Tumor Treatment in Oligometastatic Prostate Cancer
por: van Moorselaar, R. Jeroen A., et al.
Publicado: (2022)

Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer
por: Marvaso, Giulia, et al.
Publicado: (2022)

Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review
por: Koo, Kyo Chul, et al.
Publicado: (2018)

Primary Tumor Treatment in Oligometastatic Prostate Cancer: Radiotherapy Versus Radical Prostatectomy
por: Knipper, Sophie, et al.
Publicado: (2022)

Primary Tumour Treatment in Oligometastatic Prostate Cancer: Radiotherapy Versus Radical Prostatectomy
por: Ting, Francis, et al.
Publicado: (2022)

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
por: Privé, Bastiaan M., et al.
Publicado: (2020)

SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
por: Omrčen, Tomislav
Publicado: (2022)

WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?
por: Omrčen, Tomislav
Publicado: (2019)

Metastatic hormone-sensitive prostate cancer: How should it be treated?
por: López-Campos, Fernando, et al.
Publicado: (2021)

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
por: Ahmed, Kamran A., et al.
Publicado: (2013)

Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
por: Preisser, Felix, et al.
Publicado: (2021)

The metabolic repression effect of carbon-ion radiotherapy in synchronous hormone-sensitive oligometastatic prostate cancer
por: Zhang, Zhenshan, et al.
Publicado: (2023)

A Pilot Trial of Pembrolizumab plus Prostatic Cryotherapy for Men with Newly Diagnosed Oligometastatic Hormone-Sensitive Prostate Cancer
por: Ross, Ashley E., et al.
Publicado: (2019)

Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?
por: Davis, Ian D.
Publicado: (2022)

Systemic therapies for metastatic hormone‐sensitive prostate cancer: network meta‐analysis
por: Mori, Keiichiro, et al.
Publicado: (2021)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer
por: Sung, Winnie W. Y., et al.
Publicado: (2021)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
por: Li, Hengping, et al.
Publicado: (2022)

Hormonal Therapy in Metastatic Prostate Cancer: Current Perspectives and Controversies
por: Garg, Manish, et al.
Publicado: (2013)

Oligometastatic prostate cancer: Metastases-directed therapy?
por: Van Poppel, Hein, et al.
Publicado: (2016)

Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience
por: Deek, Matthew P., et al.
Publicado: (2019)

Bone flare after initiation of novel hormonal therapy in patients with metastatic hormone-sensitive prostate cancer: A case report
por: Li, Ke-Hao, et al.
Publicado: (2022)

Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer
por: Aguiar, Pedro Nazareth, et al.
Publicado: (2017)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
por: Shenoy, Niraj, et al.
Publicado: (2016)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019)

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Online Prostate-Specific Membrane Antigen and Positron Emission Tomography–Guided Radiation Therapy for Oligometastatic Prostate Cancer
por: Hrinivich, William T., et al.
Publicado: (2019)

Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer
por: Imber, Brandon S., et al.
Publicado: (2020)

Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer
por: Nakanishi, Shotaro, et al.
Publicado: (2021)

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
por: Ueda, Takashi, et al.
Publicado: (2021)

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
por: Kashiwagi, Eiji, et al.
Publicado: (2020)

Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy
por: Oing, C., et al.
Publicado: (2023)

Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions
por: Zattoni, Fabio, et al.
Publicado: (2023)

Oligometastatic Squamous Cell Transformation From Metastatic Prostate Adenocarcinoma Treated With Systemic and Focal Therapy: A Case Report
por: Autio, Karen, et al.
Publicado: (2022)

Oligometastatic Prostate Cancer
por: Stevens, Daniel J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ak90fhnr02325bvjk6nlekh46g